| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01326338 | Diarrhea | Drug: Nitazoxanide | Romark Laboratories L.C. | Phase 3 | 2005-03-01 | 2011-03-29 |
| NCT01197157 | Hepatitis C | Drug: Placebo|Drug: Nitazoxanide | National Liver Institute, Egypt | Phase 2|Phase 3 | 2010-09-01 | 2014-09-27 |
| NCT01328925 | Rotavirus Infection|Viral Gastroenteritis Due to Rotavirus | Drug: Nitazoxanide | Romark Laboratories L.C. | Phase 2 | 2005-12-01 | 2011-04-01 |
| NCT00763568 | Chronic Hepatitis C | Drug: Nitazoxanide|Biological: Peginterferon alfa-2a | Romark Laboratories L.C. | Phase 2 | 2006-08-01 | 2008-09-26 |
| NCT02612922 | Influenza | Drug: Nitazoxanide|Drug: Placebo | Romark Laboratories L.C. | Phase 3 | 2015-12-01 | 2016-08-24 |
| NCT02334163 | Hepatic Encephalopathy | Drug: Nitazoxanide|Drug: Oral lactulose|Drug: Metronidazole|Drug: Rifaximine | Ain Shams University|Al-Azhar University | Phase 2 | 2014-12-01 | 2015-01-07 |
| NCT02452905 | Bronchiolitis | Drug: Nitazoxanide|Drug: Placebo (for Nitazoxanide) | Telethon Kids Institute | Phase 2 | 2016-12-01 | 2016-05-03 |
| NCT01074203 | Hepatitis C Recurrence | Drug: Nitazoxanide | Mayo Clinic | Phase 1 | 2009-02-01 | 2012-07-27 |
| NCT01185028 | Hepatitis C Infection|HIV Infection | Drug: Nitazoxanide With Pegylated Interferon And Ribavirin | National Institutes of Health Clinical Center (CC) | Phase 1|Phase 2 | 2010-08-01 | 2013-05-16 |
| NCT02165813 | Gastroenteritis | Drug: Nitazoxanide|Drug: Placebo | Telethon Kids Institute|The University of Western Australia|Menzies School of Health Research | Phase 2 | 2014-11-01 | 2016-05-03 |
| NCT00130390 | Crohn's Disease | Drug: Nitazoxanide|Other: Placebo | Romark Laboratories L.C. | Phase 2 | 2005-08-01 | 2012-05-30 |
| NCT02684240 | Tuberculosis | Drug: Nitazoxanide|Other: Control | Weill Medical College of Cornell University | Phase 2 | 2016-02-01 | 2017-01-12 |
| NCT01227421 | Influenza | Drug: Nitazoxanide|Drug: Nitazoxanide|Drug: Placebo | Romark Laboratories L.C. | Phase 2|Phase 3 | 2010-12-01 | 2014-01-08 |
| NCT01056380 | Influenza | Drug: Nitazoxanide|Drug: Placebo | Romark Laboratories L.C. | Phase 2 | 2010-01-01 | 2012-05-30 |
| NCT02464124 | Encephalopathy, Hepatic | Drug: Nitazoxanide|Drug: Lactulose | Sherief Abd-Elsalam|Tanta University | Phase 2|Phase 3 | 2015-05-01 | 2016-10-17 |
| NCT00302640 | Rotavirus Infection|Adenoviridae Infection|Norovirus Infection | Drug: Alinia (nitazoxanide) | Romark Laboratories L.C. | Phase 2|Phase 3 | 2005-02-01 | 2012-05-30 |
| NCT00384527 | Clostridium Infections | Drug: Nitazoxanide|Drug: Vancomycin | Romark Laboratories L.C. | Phase 3 | 2006-12-01 | 2015-05-04 |
| NCT01610245 | Influenza | Drug: Nitazoxanide|Drug: Oseltamivir|Drug: Placebo Oral Tablet|Drug: Placebo Oral Capsule | Romark Laboratories L.C. | Phase 3 | 2013-03-01 | 2017-02-27 |
| NCT01770483 | Hepatitis C, Chronic|DIABETES MELLITUS Type 2 | Drug: nitazoxanide|Drug: conventional interferon alfa|Drug: Ribavirin | Services Institute of Medical Sciences, Pakistan|Getz Pharma | Phase 4 | 2011-07-01 | 2013-09-15 |
